Business Description
Beta Drugs Ltd
ISIN : INE351Y01019
Share Class Description:
NSE:BETA: Ordinary SharesTotal Employee Number:
399Compare
Compare
Traded in other countries / regions
BETA.India IPO Date
2017-10-12Description
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.95 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.6 | |||||
Debt-to-EBITDA | 3.71 | |||||
Interest Coverage | 3.04 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.46 | |||||
Beneish M-Score | -1.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19 | |||||
3-Year EBITDA Growth Rate | 17.2 | |||||
3-Year EPS without NRI Growth Rate | 10.4 | |||||
3-Year Book Growth Rate | 25.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.76 | |||||
9-Day RSI | 62.22 | |||||
14-Day RSI | 67.03 | |||||
3-1 Month Momentum % | 4.82 | |||||
6-1 Month Momentum % | -10.76 | |||||
12-1 Month Momentum % | -17.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.1 | |||||
Quick Ratio | 2.41 | |||||
Cash Ratio | 1.3 | |||||
Days Inventory | 349.53 | |||||
Days Sales Outstanding | 229.59 | |||||
Days Payable | 403.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -3.56 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.2 | |||||
Operating Margin % | 14.06 | |||||
Net Margin % | 9.69 | |||||
EBITDA Margin % | 22 | |||||
FCF Margin % | -8.94 | |||||
OCF Margin % | 20.57 | |||||
ROE % | 7.95 | |||||
ROA % | 3.71 | |||||
ROIC % | 7.86 | |||||
3-Year ROIIC % | 8.84 | |||||
ROC (Joel Greenblatt) % | 15.36 | |||||
ROCE % | 8.41 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 120.63 | |||||
PE Ratio without NRI | 120.63 | |||||
Shiller PE Ratio | 84.86 | |||||
Price-to-Owner-Earnings | 196.22 | |||||
PEG Ratio | 4.68 | |||||
PS Ratio | 11.69 | |||||
PB Ratio | 8.65 | |||||
Price-to-Tangible-Book | 9.02 | |||||
Price-to-Operating-Cash-Flow | 56.84 | |||||
EV-to-EBIT | 69.02 | |||||
EV-to-EBITDA | 53.12 | |||||
EV-to-Revenue | 11.69 | |||||
EV-to-FCF | -130.76 | |||||
Price-to-GF-Value | 1.06 | |||||
Price-to-Projected-FCF | 8.61 | |||||
Price-to-DCF (Earnings Based) | 5.06 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.04 | |||||
Price-to-Graham-Number | 5.43 | |||||
| Price-to-Net-Current-Asset-Value | 25.18 | |||||
Earnings Yield (Greenblatt) % | 1.45 | |||||
FCF Yield % | -0.77 | |||||
Forward Rate of Return (Yacktman) % | 20.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beta Drugs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,812.324 | ||
| EPS (TTM) (₹) | 17.33 | ||
| Beta | 0.6913 | ||
| 3-Year Sharpe Ratio | 0.8 | ||
| 3-Year Sortino Ratio | 1.69 | ||
| Volatility % | 66.81 | ||
| 14-Day RSI | 67.03 | ||
| 14-Day ATR (₹) | 112.190952 | ||
| 20-Day SMA (₹) | 1930.85 | ||
| 12-1 Month Momentum % | -17.29 | ||
| 52-Week Range (₹) | 990.1 - 2250 | ||
| Shares Outstanding (Mil) | 10.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beta Drugs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beta Drugs Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 1.05:1 Stock Split | 2025-03-26 | 1,842.86 (-3.73%) |
Show
Entries
Beta Drugs Ltd Frequently Asked Questions
What is Beta Drugs Ltd(NSE:BETA)'s stock price today?
The current price of NSE:BETA is ₹2090.50. The 52 week high of NSE:BETA is ₹2250.00 and 52 week low is ₹990.10.
When is next earnings date of Beta Drugs Ltd(NSE:BETA)?
The next earnings date of Beta Drugs Ltd(NSE:BETA) is .
Does Beta Drugs Ltd(NSE:BETA) pay dividends? If so, how much?
Beta Drugs Ltd(NSE:BETA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Beta Drugs Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers